Literature DB >> 25227152

Demographics and clinical characteristics of multiple sclerosis in Kuwait.

Raed Alroughani1, S F Ahmed, J Al-Hashel.   

Abstract

Using the MS registries in two MS clinics in Kuwait, we studied the demographics and clinical characteristics of multiple sclerosis (MS). Data of 736 patients (77.7% with relapsing remitting course) were analyzed. The mean age at onset and mean duration were 26.87 and 7.71 years, respectively. About 47.9% of patients had a disease duration ≤5 years. Cerebellar/brainstem and spinal manifestations were the presenting symptoms in 29.5 and 27.4%, of patients, respectively. The EDSS score was ≤3 in 72.8% of patients. We concluded that in Kuwait, the clinical characteristics of MS have important differences in terms of presentations at onset and disease progression as compared to regional cohorts.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25227152     DOI: 10.1159/000362270

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  4 in total

1.  Clinical Profile and the Extent of Disability in Multiple Sclerosis Patients in Madinah, Saudi Arabia.

Authors:  Esraa Q Alsaedi; Marwa Q Alsaedi; Farah A Mansuri
Journal:  Cureus       Date:  2022-06-11

2.  Clinical Presentations and Phenotypic Spectrum of Multiple Sclerosis at a University Hospital in Saudi Arabia.

Authors:  Saima Nazish; Rizwana Shahid; Azra Zafar; Foziah Alshamrani; Abdullah Al Sulaiman; Majed Alabdali; Danah Aljaafari; Esraa Al Wabari; Fahd A Alkhamis
Journal:  J Clin Neurol       Date:  2018-07       Impact factor: 3.077

3.  The global prevalence of familial multiple sclerosis: an updated systematic review and meta-analysis.

Authors:  Naeim Ehtesham; Maryam Zare Rafie; Meysam Mosallaei
Journal:  BMC Neurol       Date:  2021-06-28       Impact factor: 2.474

4.  A matched case-control study of risk factors associated with multiple sclerosis in Kuwait.

Authors:  Hadeel El-Muzaini; Saeed Akhtar; Raed Alroughani
Journal:  BMC Neurol       Date:  2020-02-21       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.